3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
1
Status
Completed
1
Active not recruiting
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Gynecologic
1
Conditions
Breast Neoplasms
4
Triple Negative Breast Neoplasms
2
Ovarian Neoplasms
2
Neoplasm Metastasis
2
Advanced Nonhematologic Malignancies
2
Waldenstrom Macroglobulinemia
1
Thyroid Neoplasms
1
Thyroid Carcinoma, Anaplastic
1
Somatostatinoma
1
Recurrent Malignant Solid Neoplasm
1
Recurrent Lung Squamous Cell Carcinoma
1
Precursor T-Cell Lymphoblastic Leukemia-Lymphoma
1
Precursor Cell Lymphoblastic Leukemia-Lymphoma
1
Non-hematologic Malignancy
1
Neoplasms
1
Multiple Myeloma
1
Metastatic Castration-Resistant Prostate Cancer
1
Lung Neoplasms
1
Hematologic Neoplasms
1
Fibrolamellar hepatocellular carcinoma
1
Fallopian Tube Neoplasms
1
Endometrial Neoplasms
1
Carcinoma, Renal Cell
1
Carcinoma, Non-Small-Cell Lung
1
Carcinoma, Merkel Cell
1
Burkitt Lymphoma
1
Advanced Solid Tumors
1
Advanced Solid Tumor
1
Advanced Solid Malignancies
1
Adenoma, Islet Cell
1
Interventions
Carboplatin
87
Paclitaxel
77
Bevacizumab
38
Topotecan
23
liposomal doxorubicin
22
Gemcitabine
22
Taxes
21
Cisplatin
17
Drug Therapy
14
Docetaxel
14
Cyclophosphamide
14
pembrolizumab
13
Immunoglobulin G
12
Disulfides
12
veliparib
8
rucaparib
8
mirvetuximab soravtansine
8
niraparib
7
Albumin-Bound Paclitaxel
7
sargramostim
6
Filgrastim
6
Erlotinib Hydrochloride
6
Doxorubicin
6
pazopanib
5
Granulocyte-Macrophage Colony-Stimulating Factor
5
Chemotherapy, Adjuvant
5
CP protocol
5
trebananib
4
temsirolimus
4
olaparib
4
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Completed
×
Fallopian Tube Neoplasms
×
sapanisertib
×
Clear all
NCT03648489
2024-09-20
DICE
Imperial College London
Phase 2
Completed
134 enrolled